Delphic Diagnostics
Initial Investment Date:
Q4 2005
Total Invested to Date:
£800,000
Initial Investment Stage:
development
Delphic provides a full suite of HIV diagnostics, from simple viral load testing through to advanced genetic tests, to pharmaceutical organisations and clinicians. Some of Delphic’s tests are proprietary and have been developed internally. As part of MMC's investment, the University of Liverpool's world-leading Therapeutic Drug Monitoring service, was ‘spun in’ to the business.
